Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 156-163 , July 2010

The Tumor Microenvironment in Non–Small-Cell Lung Cancer

  • Edward E. Graves, PhD
    • ,
  • Amit Maity, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Amit Maity, MD, PhD, Department of Radiation Oncology, University of Pennsylvania School of Medicine, 195 John Morgan Bldg., 3620 Hamilton Walk, Philadelphia, PA 19104
    • ,
  • Quynh-Thu Le, MD

      Affiliations

    • Corresponding Author InformationQuynh-Thu Le, MD, Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Dr., MC 5847, Stanford, CA 94305

References 

  1. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–252
  2. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408–1416
  3. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539–549
  4. Graeber TG, Peterson JF, Tsai M, et al. Hypoxia induces the accumulation of p53 protein, but the activation of a G1-phase checkpoint by low oxygen conditions is independent of p53 status. Mol Cell Biol. 1994;14:6264–6277
  5. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 2004;23:293–310
  6. Papandreou I, Cairns RA, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3:187–197
  7. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699–757
  8. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507–1514
  9. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003;2:803–811
  10. Nakao M, Ishii G, Nagai K, et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer. 2009;115:2732–2743
  11. Le QT, Shi G, Cao H, et al. Galectin-1: A link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005;23:8932–8941
  12. Le QT, Kong C, Lavori PW, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007;69:167–175
  13. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440:1222–1226
  14. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway—A report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006;24:4301–4308
  15. Giatromanolaki A, Koukourakis MI, Sowter HM, et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res. 2004;10:5566–5571
  16. de Witte JH, Sweep CG, Klijn JG, et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer. 1999;79:1190–1198
  17. Linderholm BK, Lindh B, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer. 2003;4:340–347
  18. XJ Zhan P, Wang J, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: A systematic review with meta-analysis. Lv. J Thorac Oncol. 2009;4:1094–1103
  19. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59–67
  20. Mack PC, Redman MW, Chansky K, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J Clin Oncol. 2008;26:4771–4776
  21. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10–21
  22. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol. 2003;21:2364–2371
  23. Kaanders JH, Pop LA, Marres HA, et al. Arcon: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769–778
  24. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma (Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85). Radiother Oncol. 1998;46:135–146
  25. Britten RA, Peters LJ, Murray D. Biological factors influencing the RBE of neutrons: Implications for their past, present and future use in radiotherapy. Radiat Res. 2001;156:125–135
  26. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer: A phase II study. J Clin Oncol. 1998;16:3524–3527
  27. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group (Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors). J Clin Oncol. 2000;18:1351–1359
  28. Shepherd F, Koschel G, von Pawel J, et al. Comparison of Tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international phase III catapult II Trial. Lung Cancer. 2000;29:28
  29. Williamson SK, Crowley JJ, Lara PN, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group trial S0003. J Clin Oncol. 2005;23:9097–9104
  30. Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): A Southwest Oncology Group study. Clin Cancer Res. 2004;10:5418–5424
  31. Le QT, Moon J, Redman M, et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009;27:3014–3019
  32. Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–242
  33. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer (A retrospective analysis of patients treated in the Nordic countries). Acta Oncol. 2006;45:787–795
  34. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2007;85:429–434
  35. Goodman KA, Sneed PK, McDermott MW, et al. Relationship between pattern of enhancement and local control of brain metastases after radiosurgery. Int J Radiat Oncol Biol Phys. 2001;50:139–146
  36. Tofts P, Brix G, Buckley D, et al. Estimating kinetic parameters from dynamic contrast-enhanced t 1-weighted MRI of a diffusible tracer: Standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  37. Naish JH, Kershaw LE, Buckley DL, et al. Modeling of contrast agent kinetics in the lung using T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med. 2009;61:1507–1514
  38. Schaefer JF, Vollmar J, Schick F, et al. Solitary pulmonary nodules: Dynamic contrast-enhanced MR imaging—Perfusion differences in malignant and benign lesions. Radiology. 2004;232:544–553
  39. Lin W, Guo J, Rosen MA, et al. Respiratory motion-compensated radial dynamic contrast-enhanced (DCE)-MRI of chest and abdominal lesions. Magn Reson Med. 2008;60:1135–1146
  40. Zhang M, Kono M. Solitary pulmonary nodules: Evaluation of blood flow patterns with dynamic CT. Radiology. 1997;205:471–478
  41. Ma SH, Le HB, Jia BH, et al. Peripheral pulmonary nodules: Relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer. 2008;8:186
  42. Pauls S, Mottaghy FM, Schmidt SA, et al. Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI. Magn Reson Imaging. 2008;26:1334–1341
  43. Chen X, Park R, Tohme M, et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41–49
  44. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12:3942–3949
  45. Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin aVb3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: A PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2008;49:22–29
  46. Morrison MS, Ricketts SA, Barnett J, et al. Use of a novel Arg–Gly–Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009;50:116–122
  47. Evans SM, Joiner B, Jenkins WT, et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer. 1995;72:875–882
  48. Raleigh JA, Chou SC, Arteel GE, et al. Comparisons among pimonidazole Binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 1999;151:580–589
  49. Rasey JS, Koh WJ, Grierson JR, et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985–991
  50. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113
  51. Ziemer LS, Evans SM, Kachur AV, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med. 2003;30:259–266
  52. Lewis JS, McCarthy DW, McCarthy TJ, et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–183
  53. Chapman JD, Engelhardt EL, Stobbe CC, et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 1998;46:229–237
  54. Zhang X, Melo T, Ballinger JR, et al. Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys. 1998;42:737–740
  55. Rasey JS, Wui-Jin K, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–428
  56. Cherk M, Foo S, Poon A, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926
  57. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850
  58. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F 18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–398
  59. Koch CJ, Kruuv J, Frey HE. Variation in radiation response of mammalian cells as a function of oxygen tension. Radiat Res. 1973;53:33–42
  60. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8:99–110
  61. Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009;8:947–958
  62. Zeng L, Ou G, Itasaka S, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci. 2008;99:2327–2335
  63. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res. 2006;12:5018–5022
  64. Nagy JA, Benjamin L, Zeng H, et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11:109–119
  65. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374–3378
  66. Williams KJ, Telfer BA, Shannon AM, et al. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: Pathophysiologic effects and therapeutic benefit. Mol Cancer Ther. 2007;6:599–606
  67. Williams KJ, Telfer BA, Brave S, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res. 2004;10:8587–8593
  68. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005;307:58–62
  69. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553–563
  70. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66:11520–11539
  71. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007;254:165–177
  72. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005;11:795–805
  73. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–3335
  74. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  75. Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66:3197–3204
  76. Cerniglia GJ, Pore N, Tsai JH, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy andradiotherapy efficacy. PLoS ONE. 2009;4:e6539
  77. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 2008;27:5497–5510
  78. Gupta AK, Soto DE, Feldman MD, et al. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung. 2004;182:151–162
  79. Lee SH, Kim HS, Park WS, et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS. 2002;110:587–592
  80. Kim IA, Bae SS, Fernandes A, et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 2005;65:7902–7910
  81. Prevo R, Deutsch E, Sampson O, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res. 2008;68:5915–5923
  82. Qayum N, Muschel RJ, Im JH, et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 2009;69:6347–6354
  83. Gupta AK, Cerniglia GJ, Mick R, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 2005;65:8256–8265
  84. Jiang Z, Pore N, Cerniglia GJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2006;67:9252–9259
  85. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Res. 2006;66:9252–9259
  86. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881–890
  87. Swinson DE, Jones JL, Cox G, et al. Hypoxia-inducible factor-1 alpha in nonsmall cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int J Cancer. 2004;111:43–50
  88. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer. 2005;49:325–335
  89. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001;61:7992–7998
  90. Kon-no H, Ishii G, Nagai K, et al. Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer. 2006;54:409–418
  91. Simi L, Venturini G, Malentacchi F, et al. Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer. 2006;52:59–66
  92. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003;21:473–482
  93. Malentacchi F, Simi L, Nannelli C, et al. Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer. 2009;64:271–276
  94. Minami K, Saito Y, Imamura H, et al. Prognostic significance of p53, Ki-67, VEGF and glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer. 2002;38:51–57
  95. Nguyen XC, Lee WW, Chung JH, et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: Correlations and prognostic values. Eur J Radiol. 2007;62:214–219

 Supported by NIH R01 CA093638 (AM), NIH R01 CA131199 (EG), and NIH PO1 CA67166 (Q-TL).

 Q-TL received research funding from GlaxoSmithKline, Amgen, and Varian for investigator initiated studies unrelated to the discussed topics.

PII: S1053-4296(10)00011-1

doi: 10.1016/j.semradonc.2010.01.003

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 156-163 , July 2010

Article Tools

* Image Usage & Resolution